Tourette Syndrome (TS) – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040
- Published Date : November 27, 2025
- Updated On : June 25, 2026
- Pages : 55
Tourette Syndrome Global Epidemiology Insights and Disease Burden
Thelansis’s “Tourette Syndrome (TS) Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Tourette Syndrome (TS) Overview
Tourette syndrome (TS) is a childhood-onset neurodevelopmental disorder defined by multiple motor tics and at least one vocal tic persisting for over a year. It arises from cortico-striato-thalamo-cortical (CSTC) circuitry dysregulation and is highly heritable, with ADHD and OCD as frequent, functionally impairing comorbidities. Tics classically wax and wane, typically attenuating by late adolescence. Diagnosis is strictly clinical following DSM-5 criteria. Management prioritizes psychoeducation and behavioral interventions—specifically Comprehensive Behavioral Intervention for Tics (CBIT)—as the first-line standard. When pharmacotherapy is required, alpha-2 agonists (clonidine, guanfacine) offer modest benefit with favorable tolerability. More severe tics are traditionally managed with D2-blocking antipsychotics (aripiprazole, haloperidol). Crucially, the pharmacological landscape is shifting away from metabolic-heavy D2 blockers; ecopipam, a first-in-class selective D1 receptor antagonist, recently demonstrated significant efficacy in Phase 3 trials and is poised to become the first non-antipsychotic targeted therapy for TS. Deep brain stimulation remains reserved for severe, refractory adult cases.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
Tourette Syndrome Global Epidemiology Insights and Disease Burden
Thelansis’s “Tourette Syndrome (TS) Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Tourette Syndrome (TS) Overview
Tourette syndrome (TS) is a childhood-onset neurodevelopmental disorder defined by multiple motor tics and at least one vocal tic persisting for over a year. It arises from cortico-striato-thalamo-cortical (CSTC) circuitry dysregulation and is highly heritable, with ADHD and OCD as frequent, functionally impairing comorbidities. Tics classically wax and wane, typically attenuating by late adolescence. Diagnosis is strictly clinical following DSM-5 criteria. Management prioritizes psychoeducation and behavioral interventions—specifically Comprehensive Behavioral Intervention for Tics (CBIT)—as the first-line standard. When pharmacotherapy is required, alpha-2 agonists (clonidine, guanfacine) offer modest benefit with favorable tolerability. More severe tics are traditionally managed with D2-blocking antipsychotics (aripiprazole, haloperidol). Crucially, the pharmacological landscape is shifting away from metabolic-heavy D2 blockers; ecopipam, a first-in-class selective D1 receptor antagonist, recently demonstrated significant efficacy in Phase 3 trials and is poised to become the first non-antipsychotic targeted therapy for TS. Deep brain stimulation remains reserved for severe, refractory adult cases.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)